AIDP receives patent for multi-ingredient prebiotic formula

February 3, 2021
Alissa Marrapodi

AIDP, Inc. has secured U.S. patent 10,881,675 B2 on Jan. 5, 2021 for the combination of Actazin, a green or gold kiwi extract powder rich in the digestive enzyme actinidin, with PreticX xylooligosaccharide (XOS), a prebiotic.

AIDP, Inc. (City of Industry, CA) secured U.S. patent 10,881,675 B2 on Jan. 5, 2021 for the combination of Actazin, a green or gold kiwi extract powder rich in the digestive enzyme actinidin, with PreticX xylooligosaccharide (XOS), a prebiotic. 

In a recent double-blind, placebo-controlled clinical trial, healthy subjects were randomized into three groups: placebo, 600 mg of Actazin, or 600 mg Actazin plus 1.4 g of 70% PreticX for 28 days. Actazin in combination with PreticX gave significantly improved scores over the other two groups, demonstrating improved bowel regulatory of the participants.

“This patent is a great addition to AIDP’s prebiotic portfolio,” said Jennifer Gu, PhD, vice president of research and development of AIDP, in a press release. “Our research agenda focuses on providing proven results to our customers. Securing this patent ensures our customers have a verified unique product for daily digestive support.”